Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans

– Myeloid dosed MT-101 in a patient with refractory PTCL within 18 months, illustrating the potential of mRNA therapies to help patients sooner and to accelerate Myeloid’s portfolio-

– Myeloid achieved an unprecedented, reduced vein-to-vein time of eight days with this patient dosing-

– MT-101 represents a new class of non-T cell CAR’s being tested in the clinic for their ability to modify the tumor microenvironment and stimulate a robust anti-tumor immune response-

Excerpt from the Press Release:

CAMBRIDGE, Mass., May 11, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”, or the “Company”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced the first patient dosed in the IMAGINE Study, a Phase 1/2 clinical study of MT-101, in patients with refractory or relapsed peripheral T cell lymphoma (PTCL), an aggressive form of non-Hodgkin lymphoma. MT-101 is the first mRNA engineered CAR monocyte (CAR-M) derived from the Company’s proprietary ATAK™ platform. MT-101 targets CD5, a surface receptor present in many T cell malignancies. The ATAK™ CAR is proprietary to the company and specifically designed to promote broad anti-tumor activity. At Day 28, the primary endpoint for safety and tolerability, the patient had no dose limiting toxicities, no cytokine release syndrome (CRS), and no immune effector cell-associated neurotoxicity syndrome (ICANS).    

“We are pleased to announce the initiation of dosing in the IMAGINE clinical trial, which represents a major milestone in our efforts to provide treatment with CD5 ATAK cells for patients with relapsed or refractory PTCL,” said Michele Gerber, MD, MPH, Chief Medical Officer of Myeloid. “Currently, we are continuing through the dose-escalation cohorts of IMAGINE, which is designed to assess the safety and tolerability, optimal dose regimen, tumor penetration and preliminary efficacy of MT-101 in patients with PTCL. Following conclusion of Phase 1, we expect to expand quickly into the Phase 2 portion of this study, which we designed to support registration of MT-101.”

“MT-101, Myeloid’s leading mRNA-engineered monocyte, was advanced from conception and preclinical proof of concept to our first dose in human in just eighteen months. Importantly, this is the first instance of an engineered monocyte cell product delivered to a patient with a significantly reduced vein-to-vein time of just eight days,” said Daniel Getts, PhD, CEO of Myeloid. “Overall, this achievement highlights Myeloid’s ability to produce scalable cell therapy products in an efficient manner, and we are optimistic about the impact this program can provide to PTCL patients and their families going forward.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release